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Abstract
Background: Depression is a common illness, often treated in primary care. Many studies have reported undertreatment
with antidepressants in primary care. Recently, some studies also reported overtreatment with antidepressants. The present
study was designed to assess whether treatment with antidepressants in primary care is in accordance with current
guidelines, with a special focus on overtreatment.
Methodology: We used baseline data of primary care respondents from the Netherlands Study of Depression and Anxiety
(NESDA) (n = 1610). Seventy-nine patients with treatment in secondary care were excluded. We assessed justification for
treatment with antidepressant according to the Dutch primary care guidelines for depression and for anxiety disorders. Use
of antidepressants was based on drug-container inspection or, if unavailable, on self-report. Results were recalculated to the
original population of primary care patients from which the participants in NESDA were selected (n = 10,677).
Principal Findings: Of 1531 included primary care patients, 199 (13%) used an antidepressant, of whom 188 (94.5%)
(possibly) justified. After recalculating these numbers to the original population (n = 10,677), we found 908 (95% CI 823 to
994) antidepressant users. Forty-nine (95% CI 20 to 78) of them (5.4%) had no current justification for an antidepressant, but
27 of them (54.5%) had a justified reason for an antidepressant at some earlier point in their life.
Conclusions: We found that overtreatment with antidepressants in primary care is not a frequent problem. Too long
continuation of treatment seems to explain the largest proportion of overtreatment as opposed to inappropriate initiation
of treatment.
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Introduction
Depression is a common disorder which is associated with a
great amount of morbidity because of its highly recurrent and
chronic nature.[1] Most patients with depression are treated in
primary care.[2,3] Guidelines on the treatment of depression in
primary and secondary care consider treatment with antidepres-
sants and/or psychotherapy indicated for all patients with major
depressive disorder (MDD).[4–10] According to these guidelines
the treatment should be continued for 6 months after remission
(continuation treatment) of a first episode, while it should be
continued for one or more years (maintenance treatment) in
patients with a recurrent MDD or chronic depression.[4–10]
Various studies reported that treatment of depression in primary
care is not according to guideline recommendations.[11–16] Most
studies reported undertreatment, especially with antidepressants of
patients with MDD.[11–16] However, in recent years there has
also been a lot of attention for overtreatment with antidepres-
sants.[17–19] The fact that in the last 6 months of 2005 760,000
people in the Netherlands (population 16.500.000) were prescribed
an antidepressant, according to the Dutch Foundation for
Pharmaceutical Statistics (SFK, www.sfk.nl), led to discussions in
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the Dutch media and among professionals. High numbers were
recently also reported in the US and UK, which also led to
discussions.[20–22] A few studies on overtreatment with antide-
pressants suggested that this is mainly due to prescription of these
drugs to patients with milder forms of depression, such as
dysthymia (Dysth) or minor depression (miD).[17,18,23–26]
Especially the prescription of antidepressants to patients with
miD is controversial, as there is no evidence for the efficacy of
antidepressants in this condition.[27–29] On the other hand, even
patients without a depression might receive antidepressants for
another justified indication such as anxiety disorders and pain, for
which several antidepressants are also registered.
The aim of this study was to evaluate whether the statements
reported in the media and a few articles in the literature about
widespread overtreatment with antidepressants were true. There-
fore, we wanted to assess to what extent the use of antidepressants
is in accordance with the Dutch primary care guideline for
depression (which is comparable to other international guidelines)
as well as for anxiety disorders, with a focus on overtreatment.
Methods
This study was conducted with baseline-data from the Nether-
lands Study of Depression and Anxiety (NESDA, www.nesda.nl), a
large prospective cohort study on depression and anxiety disorders
among respondents aged between 18 and 65 years, recruited from
the community, primary care and (secondary) mental health care.
Detailed information on the objectives and methods of NESDA
were published elsewhere.[30]
Participants
For this study we selected from the NESDA database only those
respondents who were recruited in primary care. In short the
recruitment in primary care was as follows. A screening
questionnaire was sent to a random sample of 23,750 people
from 65 general practitioners (GPs) who had consulted their GP in
the past four months, irrespective of reason for consultation. In the
Netherlands patients are listed with a single GP or GP practice.
The GP is the gatekeeper to secondary care, access to secondary
(mental) health care is impossible without a reference from a GP.
The screening questionnaire consisted of the Kessler-10 (K-10),
which has proven screening qualities for affective disorders, and
five additional questions asking about the presence of specific anxiety
disorders. [31,32] A positive score was defined as a validated K-10
score of $20, or a positive score on any of the five anxiety
questions.[32] Almost half of the sample (n = 10,706; 45%)
returned the screener. Responders to the screener were slightly
more often female and older than non-responders.[30,33]
Although having to take small age and sex differences into
account, we consider this sample representative of patients
consulting their GP in the Netherlands.[33]
Those who screened positive (n = 4592) were approached for a
telephone interview with the short form sections of the CIDI (CIDI-SF)
which has proven screening qualities with a high sensitivity for
detecting mental disorders.[34] Specifically trained research staff
(mainly psychologists and research nurses) conducted the tele-
phone interview.
All persons who screened positive on the CIDI-SF (n= 898), as
well as 196 out of 278 randomly selected persons with a positive K-
10 plus, but not fulfilling CIDI-SF criteria and a random selection
of 516 screen negatives (healthy controls) participated in the
baseline assessment of NESDA (n= 1610), which consisted of a
face-to-face interview.
The 79 respondents already receiving treatment for psychiatric
conditions in secondary care (defined as more than one contact
with either an institute for mental/psychiatric health care or an
independent psychiatrist) were excluded from our study sample,
yielding a total sample of 1531 respondents for the present
analyses.
Description of Procedures or Investigations undertaken
Measures. As part of the screening procedure, all
respondents filled out the K-10 plus.
Demographic data (age, gender, ethnicity, education) were
assessed during the baseline interview.
Current and lifetime diagnoses of MDD, Dysth, current
diagnosis of miD, comorbid anxiety disorders (social phobia,
panic disorder, agoraphobia, generalized anxiety disorder) based
on DSM-IV were assessed with a structured interview, the World
Health Organization Composite International Diagnostic Interview – lifetime
version 2.1 (CIDI), which is considered the gold standard for
diagnosing depressive and anxiety disorders in large epidemiolog-
ical studies.[35–37] Specifically trained research staff (mainly
psychologists and research nurses) conducted the baseline
interview including the CIDI.
From the data of the CIDI interview, in which all depressive
symptoms were listed separately, we created a variable for depressive
symptoms, defined as having had one or more DSM-IV symptoms
of depression during at least two weeks lifetime with at least either
anhedonia or depressed mood, without fulfilling the criteria for
diagnosis of MDD or dysthymia. From this data we also created a
variable ‘‘chronic MDD’’, defined as having had a lifetime diagnosis
of MDD and 24 months of (probably uninterrupted) symptoms of
depression in the past five years as recorded with the life-chart
method. The life chart is a method for recalling depressive
symptomatology, the respondent was asked during the interview
to mention several important (personal) events from the last several
years and was subsequently asked to recall if there was some
depressive symptomatology at that point. The life chart has been
proven useful to assess the course of illness in patients with mood
disorders.[38–40]
Outcome variables
Whether respondents used antidepressants was based on drug
container inspection of all drugs used in the past month at baseline
and classified according to the World Health Organization
Anatomical Therapeutic Chemical (ATC) classification. If respon-
dents had forgotten to take the medication to the interview, their
use was based on self-report (done for 35.3% of all subjects). The
use of two different methods for assessing antidepressant drugs was
not a problem in the current study, as we were not interested in
patient compliance, for which self report and drug container
inspection can give very different results, but only in physician
prescription behaviour. We therefore used the drug container
inspection only to assess which medications were used and not for
pill counts. Use of antidepressants included selective serotonin
reuptake inhibitors (ATC-code N06AB), tricyclic antidepressants
(N06AA) and other antidepressants (N06AF/N06AX). St John’s
wort was not considered an antidepressant.
Justification for treatment with an antidepressant
To determine the justification for treatment with an antide-
pressant, we followed the recommendations from the guidelines
for depression and for anxiety disorders of the Dutch General
Practitioner’s Association (NHG). [7,41] Treatment was consid-
ered justified when it was mentioned in the guideline as (one of the)
first step option(s) and considered possibly justified when it was
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mentioned as (one of the) second step option(s). For depressive
disorders the depression guideline recommends the use of an
antidepressant during six months after response for a first episode
of MDD as one of the first step treatment options, although
dependent on the degree of suffering or dysfunction. As
dysfunction is a criterion for the diagnosis of MDD and patients
consulted their physician, we assumed that probably most had at
least some degree of suffering or dysfunction. Therefore, we
considered treatment with antidepressants justified when a
respondent had suffered an episode of MDD in the past year. In
case of recurrent or chronic MDD the guideline recommends one
to five years of maintenance treatment, with the option for longer
in patients with previous recurrences after withdrawal of
antidepressants. Therefore, treatment of chronic or recurrent
MDD for up to two years was considered justified, all treatment
longer than two years was considered possibly justified. In case of
dysthymia an antidepressant is mentioned in the depression
guideline as (one of the) second step option(s) and therefore
considered possibly justified. Antidepressants were not considered
justified for depressive states not fulfilling criteria for MDD or
dysthymia.
As antidepressants are also registered for the treatment of
anxiety disorders, we also considered treatment with antidepres-
sants justified in case the guideline recommendations from the
anxiety disorder guideline were followed. This guideline recom-
mends treatment with an antidepressant in case of the presence of
an anxiety disorder in the last year, with the option (i.e. possibly
justified) to continue the treatment for a longer period.
Overtreatment was considered present when a respondent
received an antidepressant without justification or possible
justification, i.e. without a non-recurrent (i.e. single) episode of
MDD or dysthymia in the past year, or an anxiety disorder or
recurrent MDD or chronic depression in lifetime.
Ethics
The study protocol of NESDA was approved centrally by the
Ethical Review Board of the VU University Medical Center and
subsequently by local review boards of each participating center.
After full verbal and written information about the study, written
informed consent was obtained from all participants at the start of
baseline assessment. A full ethics statement of NESDA is found
elsewhere. [30]
Statistical methods. Descriptive statistics and frequencies
were used to describe the use of AD and psychological treatment.
We recalculated the found numbers and percentages of justified
and unjustified treatment with antidepressants in our sample to the
original population of 10,677 persons who returned a completed
K-10 plus screener questionnaire. This backward projection was
done in several steps, which can be derived by reading Figure 1
from the bottom up, or from table 1.
In the first step, we split our sample into four groups; no use of
an antidepressant, justified use, possibly justified use and
unjustified use. We will refer to these groups as ‘‘justification
groups’’. After that, we registered the number of screen-positives
and screen-negatives in each of the justification groups. These
numbers were then multiplied by a correction factor (respectively
Figure 1. Recruitment flow respondents.
doi:10.1371/journal.pone.0014784.g001
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total screen-positives divided by screen-positives in sample (4592/
1024) or total screen-negatives divided by number of screen-
negatives in our sample (6085/506)) to calculate the estimated
number of persons from each justification group in the original
screen-positive and screen-negative groups. Finally, we added up
the estimated numbers screen-positives and negatives for each
justification group.
A 95% confidence interval (95% CI) was calculated for all
estimated numbers. This was done by first calculating the standard
error of the proportion with the proper mathematical formula.
This number was then multiplied by 1.96 and subtracted and
added to the proportion in order to get the 95% CI of the
proportion, which could then be recalculated to the 95% CI of the
absolute number by multiplying by n.
We used a Chi square statistic to test for significant differences
in justification for an antidepressant between antidepressant users
with no/mild/moderate/severe MDD.
All statistical calculations were performed using SPSS for
Windows Release 16.0.
Results
Study population
The average age of the population was 45.8 years, 1054 (68.8%)
of respondents were female and 477 (31.2%) male.
The diagnoses of the respondents with lifetime depression/
depressive symptoms (n= 1064, of whom 651 with a comorbid
anxiety disorder) were as follows: 807 respondents had a lifetime
MDD of whom 428 in the past year; 23 had a lifetime Dysth
without history of MDD of whom 16 in the past year; and 234 had
a lifetime miD or depressive symptoms in lifetime without a history
of MDD or Dysth, of whom 44 had a miD in the past month
(incidence in last year unknown). The diagnoses of the respondents
with a lifetime anxiety disorder (n = 762) were: 345 patients with
social phobia; 344 patients with a panic disorder (with or without
agoraphobia); 131 patients with agoraphobia; and 330 patients
with a generalized anxiety disorder (324 patients had more than
one anxiety disorder).
Justified and non-justified treatment
Of the respondents with a depression/depressive symptoms
(MDD, dysthymia, miD or depressive symptoms, n= 1064), 189
(17.8%) used an antidepressant, of whom 75 (39.7%) had a
justification, 68 (36.0%) a possible justification and 46 (24.3%) did
not have a justification.
However, of the 46 antidepressants users with a depression/
depressive symptoms without a justification for treatment with an
antidepressant (non-recurrent MDD, miD or depressive symp-
toms) nine had only a depression/depressive symptoms and 37 had
a lifetime anxiety disorder (26 in the past year), which means that
the antidepressant may have been prescribed for the anxiety
disorder rather than the depression. This means that in only nine
patients (4.5%) with a depression/depressive symptoms treatment
was not justified.
Of the 111 respondents with a lifetime anxiety disorder without
a depression/depressive symptoms eight patients (10.1%) used an
antidepressant, in three this was justified and in five possibly
justified.
Only 2 (0.6%) of the 356 respondents without a lifetime
depression or anxiety disorder used an antidepressant. This
treatment obviously was not justified.
Table 2 shows a summary of justified and not justified treatment
in our sample. In total 11 respondents used an antidepressant
without a definite or possible justified reason. Eight of them used a
SSRI, one a TCA (at low dose) and two another antidepressant;
the duration of antidepressant use varied from 0 to 120 months,
with a median of 48 months. Nine of these respondents had a
depression/depressive symptoms (six a single episode of MDD
more than one year ago, three miD or depressive symptoms). They
represent 0.77% of the 1175 respondents with a lifetime
depression or anxiety disorder. The other two represent 0.56%
of the 356 respondents without a depression/depressive symptoms
or anxiety disorder. Thus, 6 of the 11 respondents (54,5%) had a
justified reason for treatment with an antidepressant at some
earlier point in their life because of an episode of MDD.
Table 1. Results of recalculation of justified and unjustified antidepressant use to screener population.
Study sample (n =1531) Screen positive (n=4592) Screen negative (n =6085)
Screener population
(n =10,677)
Definitely justified AD use 95 (47.7%) 94 * 4.5(1) = 422 1* 12.0(2) = 12 434 (394–474)(3)
Possibly justified AD use 93 (46.7%) 92 * 4.5(1) = 413 1* 12.0(2) = 12 425 (385–465)(3)
Unjustified AD use 11 (5.5%) 11 * 4.5(1) = 49 0 * 12.0(2) = 0 49 (20–78)(3)
Total 199 (100%) 197 * 4.5(1) = 884 2 * 12.0(2) = 24 908 (823–994)(3)
(1)Correction factor screen-positive group: total number of screen-positives divided by number of screen-positives in the study sample (4592/1024 = 4.5).
(2)Correction factor screen-negative group: total number of screen-negatives divided by number of screen-negatives in the study sample (6085/506 = 12.0).
(3)95% Confidence Interval.
doi:10.1371/journal.pone.0014784.t001
Table 2. Treatment with antidepressants and justification for
treatment.
Justification for
treatment No AD AD Total
Unjustified 566 (98.1%) 11 (1.9%) 577
Possibly justified 225 (70.8%) 93 (29.3%) 318
Definitely justified 541 (85.1%) 95 (14.9%) 636
Total 1332 (87.0%) 199 (12.9%) 1531
Treatment was considered definitely justified in case of a MDD in the past year,
or recurrent or chronic MDD with antidepressant treatment #24 months, or an
anxiety disorder in the past year.
Treatment was considered possibly justified in case of dysthymia in the past
year, or a recurrent or chronic MDD with antidepressant treatment for more
than 24 months, or an anxiety disorder over one year ago.
All other antidepressant treatment was considered unjustified.
All numbers are absolute number of respondents (percentage of total
respondents in row).
AD= antidepressant.
doi:10.1371/journal.pone.0014784.t002
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Table 3 shows the relation between severity of depression at
baseline and antidepressant use. This table shows that antidepres-
sant users with a mild (recurrent) MDD are less often classified as
definitely justified AD use. We performed a Chi square test
comparing the justification groups for antidepressant users with
moderate to severe (recurrent) MDD to antidepressant users with
no MDD or mild (recurrent) MDD. The difference was significant
(p = 0.015), antidepressant users with moderate to severe (recur-
rent) MDD more often had a justified reason for the use of an
antidepressant compared to antidepressant users with no MDD or
mild (recurrent) MDD.
Use of antidepressants in the primary care population
With the selection procedure as described in the method
section, we can calculate what our findings mean for the total
population of respondents (n = 10,677) who returned the K-10
plus (table 1).
In our sample there were 188 antidepressant users with justified
antidepressant use of whom 95 (50.5%) with a definite justified
reason, and 93 (49.5%) with a possible justified reason: 2 among
the respondents with a negative K-10 plus (n = 6085, of whom 506
participated in the study) and 186 among the respondents with a
positive K-10 plus (n = 4592, of whom 1023 participated).
Recalculated to the respondents who completed the K-10, there
are 24 (95% CI (0 to 57) antidepressant users with a definite or
possibly justified reason in the screen-negative group and 835
(95% CI 726 to 943) in the screen-positive group.
All 11 respondents who used an antidepressant without a
definite or possible justified reason had a positive K-10 plus. The
total number of antidepressant users without a justified reason
among all respondents with a positive K-10 plus can be
recalculated at 49 (95% CI 20 to 78). As there were no
antidepressant users without indication with a negative K-10 plus,
the total number of respondents who used an antidepressant
without indication among all 10,677 people who completed the K-
10 plus, is also 49 (95% CI 20 to 78). K-10 plus results were
unknown for one respondent without antidepressant use.
Combining the results of antidepressant users with and without
justification, recalculated to the sample of 10,677 GP patients from
65 GPs who had consulted their GP in the past four months
irrespective of reason for consultation and did return a completed
screening questionnaire, 908 (8.5%), (95% CI 823 to 994), used an
antidepressant of whom 859 (94.6% of the antidepressant users)
with a definite (n = 434, 47.8%) or possible (n = 425, 46.8%)
justification in accordance with the guideline and 49 patients
(5.4% of the antidepressant users) without justification.
Discussion
Summary of main findings
The main finding of our study is that overtreatment with
antidepressants did not appear to be a very frequent problem in
Dutch primary care. Of all GP patients (and after excluding
patients who were treated in secondary care including hospitals,
institutes for mental health care and psychiatrists with private
practices) 8.5% received an antidepressant. When compared
with the guidelines of the Dutch General Practitioner’s
Association (NHG), 94.6% of the antidepressant use was in
accordance with the guideline (47.8% definitely and 46.8%
possibly) while only 5.4% was not. The latter was for the large
part not due to treatment of mild forms of depression or patients
without psychiatric diagnoses, but to non-justified long contin-
uation of antidepressant treatment in patients who at some
earlier point in their life had a justified reason for treatment with
an antidepressant.
Strengths and limitations of the study
The current study has several very strong points. First, we used
a screening method to recruit participants which did not affect the
awareness of patient’s psychiatric status for GPs in our study. This
means that the GPs could only rely on their own diagnostic
judgments also for their prescription of antidepressants. The
second strength of this study is its large sample size, which is rather
rare in a primary care study. The third strength is that all patients
were diagnosed based on a structured interview and not on the
GPs’ records.
However there are also limitations. First, the last mentioned
strength is also a weakness, as the structured interview we used (the
CIDI) does not assess the degree of suffering and dysfunction,
which should be part of the GPs’ consideration for antidepressant
treatment according to the guideline recommendations. Second,
the representativeness of the population may be limited. The GPs
in this study, and thus their patients, may not be representative for
all Dutch primary care practices, as these practices/GPs agreed to
Table 3. Severity of depression at baseline and indication for treatment with an antidepressant, based only on depression
diagnosis.
Definitely justified AD
users (n,%)
Possibly justified AD
users (n,%)
Unjustified AD users
(n,%) Total (n)
MDD Single Mild 7 (24%) 6 (21%) 16 (55%) 29
MDD Recurrent Mild 12 (39%) 19 (61%) N/A 31
MDD Single Moderate 19 (54%) 7 (20%) 9 (26%) 35
MDD Recurrent Moderate 9 (64%) 5 (36%) N/A 14
MDD Single Severe 11(33%) 8 (24%) 14 (42%) 33
MDD Recurrent Severe 17 (53%) 15 (47%) N/A 32
Dysthymia N/A 8 (100%) 0 (0%) 8
miD/depressive symptoms N/A N/A 7 (100%) 7
Total 75 68 46 189
N/A= not applicable.
Respondents with a recurrent MDD and possibly justified AD use had a possible justification because they had used an antidepressant for more than 2 years.
doi:10.1371/journal.pone.0014784.t003
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participate in the NESDA study, and thus have interest in
psychiatric research. This may be associated with a better
compliance to the guidelines for depression and for anxiety
disorders. Next to that, according to the SFK about 760,000
Dutchmen were prescribed an antidepressant (about 6.3% of the
adult population) in the last 6 months of 2005. In our primary care
sample we recalculated that 8.5% used an antidepressant. This
higher percentage may be explained by the fact that respondents
were selected among the patients who consulted their GP in the
last four months. The non-response to the screening questionnaire
did not seem to be biased with regard to psychopathology.[33]
Fourth, we did not have access to the full electronic patient file
from the GPs. Therefore we did not know why they prescribed an
antidepressant. This might have been of interest, as antidepres-
sants can also be prescribed for other indications than depression
or anxiety disorder. Some antidepressants including TCAs at low
dose for example are used for neuropathic pain. However, if any
effect, this would result in an ever lower estimation of
overtreatment with antidepressants in our sample. In addition,
we could not determine the ground on which the GPs based their
treatment decisions, therefore we could not determine if a decision
to (dis)continue an antidepressant was according to guideline
recommendations. This applies especially to the category ‘possibly
justified’ in patients who had recovered from a recurrent
depressive episode more than two years ago, as we do not have
information as to why the antidepressant was continued in these
patients. Among them are definitely patients who continue their
antidepressants for good reasons, e.g. patients who had stopped
their antidepressant after a recurrent episode and who developed a
new recurrence, and patients who tapered off and subsequently
developed minor symptoms and therefore restarted medication.
This limitation also means that we were unable to estimate the
severity of symptoms at the time the antidepressant was started.
Table 3 showed that some respondents with a mild episode of
MDD received treatment with antidepressants. The guideline at
time of the study does not differentiate between mild and
moderate to severe depressive episodes in its recommendations,
but more recent guidelines do. For example the new Dutch
multidisciplinary depression guideline is much more conservative
and recommends to reserve treatment with antidepressants for
patients with more severe depressive states.[42] It is unclear
whether the patients with mild symptomatology at baseline had
more severe symptomatology at the time the antidepressant
treatment was initiated.
A final limitation is the cross-sectional design of the study, as a
result of which the start of symptoms and time of remission could
not be determined precisely. We allowed treatment with
antidepressants in case of a MDD in the past year. In some cases
treatment probably should have been stopped before the
interview, because the patient had been in remission for (more
than) 6 months. Because of the cross-sectional design, we also had
to rely on recall of symptoms of depression and anxiety during the
past year and for lifetime diagnoses. Several researchers have
questioned the reliability of retrospective recall of symptoms
during a single interview in persons with a history of depres-
sion.[43,44]
Comparison with existing literature
Several previous studies also looked at rates of overtreatment,
with various outcomes. The major contrast with our study is that
these studies only looked at relative small groups of GP patients
and did not allow recalculation of the results to the total
population of GP patients. Two of the previous studies found
high rates of overtreatment: 25% (Sihvo et al.) and even 35%
(Berardi et al.).[17,18] Berardi et al. described a group of 361
primary care patients of whom 82 used an antidepressant. They
only considered treatment with antidepressants indicated for
current depression, ignoring possible continuation or maintenance
treatment and other indications for the use of antidepressants like
anxiety disorders. This is a rather limited definition, as
continuation treatment is a well-established part of depression
treatment and many antidepressants are also registered for anxiety
disorders. Sihvo et al. described a group of 526 patients who used
an antidepressant. They adopted a definition of overtreatment
slightly broader than ours. Treatment was considered ‘‘non-
psychiatric’’ in case there was no CIDI diagnosis of MDD, Dysth,
anxiety disorder (generalised anxiety, social phobia, panic disorder
or agoraphobia), bipolar disorder or alcohol dependence in the last
12 months.
The third previous study (Cameron et al) reported a small
percentage (exact percentage not mentioned) of overtreatment in a
Scottish primary care sample of 120 antidepressant users.[19]
They did not have a diagnosis based on a structured interview, but
used a cutt-off score of the Hospital Anxiety and Depression Scale
(HADS). Of their sample 45 had ‘‘no depression’’, 34 had a
‘‘possible depression’’ and 41 had ‘‘probable depression.’’ In the
respondents with ‘‘no depression’’, they reported that 32 had a
history of depression (as recorded by the GP), 5 had anxiety
disorder, 5 had neuropathic pain and for only 3 it remained
unclear why they received an antidepressant.
It can be argued that our definition of non-justified antidepres-
sant use is rather small, and that in reality more patients in our
sample did not actually need an antidepressant. First, we defined
lifelong treatment non-justified only for patients without a definite
or possible justification. This created the problem of how to
classify the category ‘possible justified’ for treatment beyond two
years of patients with a recurrent depression, while most guidelines
recommend several years and only for a (non-specified) subgroup
lifelong treatment. Second, also in case of anxiety disorders it
could be argued that lifelong treatment is unnecessary in many if
not most cases. Third, the diagnosis chronic MDD was based on
the self-report of 24 months (of probably uninterrupted) symptoms
of depression in the past five years according to the life chart and a
lifetime diagnosis of MDD. It could very well be that these patients
had no chronic MDD, but just symptoms of depression during two
or more years. This would mean that in more patients
antidepressants would be unnecessary. When we would have
classified all possible justified cases as overtreatment the percent-
age would indeed rise substantially: from 5.4% to 52.2%, which is
much higher than Berardi et al. and Sihvo et al. and clearly
illustrates the importance of a clear definition of overtreatment.
We think however that our definition including life long treatment
for patients with recurrent depressive episodes is justifiable,
considering the high recurrence rate of depression, especially after
multiple episodes.[45,46] As discussed above, at least part of the
respondents with a possible justification will have a very good
reason for the use of an antidepressant. Moreover, there could be
patients without a justified reason for the use antidepressants, for
whom the physician (or the patient himself) found an antidepres-
sant needed, e.g. because of residual symptoms after a single
episode of MDD. One could also argue that, although not
indicated according to the guideline, this is justified treatment.
If indeed the percentage of overtreatment is lower in the
Netherlands than in other countries: what would be the
explanation? A possible explanation is the difference in primary
care systems. In the Netherlands, the GP is the gatekeeper to
secondary and mental health care; patients need a reference from
the GP before they can consult mental health care. Secondly,
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Dutch GPs have been trained during the last years in how to
diagnose and treat depression and anxiety disorders, as part of the
implementation of the Dutch primary care guidelines. This also
implies that our results probably cannot be generalized globally, as
primary healthcare systems vary across countries.
Another explanation for the difference could be that antide-
pressant use in our study was based on drug-container inspection
in most patients and on self-report in a minority of cases, while the
Dutch Foundation for Pharmaceutical Statistics (SFK, www.sfk.nl)
data are based on pharmacy prescription data. From previous
studies it is known that many patients do not pick up their
prescription or do not take their medication.[47,48]
In this study we focused on overtreatment with antidepressants,
and therefore we looked at whether patients received an
antidepressant without a justified reason. However, ‘‘justified’’
does not mean ‘‘needed’’. Patients with a mild or even moderately
severe episode of MDD do not necessarily need treatment (either
an antidepressant or psychotherapy), although they do have a
justified reason for treatment with an antidepressant. New
guidelines like the recent 2009 update of the Dutch multidisci-
plinary guideline for depression recommend to reserve antide-
pressants for patients with moderate to severe depression.[42]
Therefore, an alternative interesting question is: who needs an
antidepressant, and how many of the patients who need an
antidepressant do actually receive an antidepressant. This
however, was not the focus of our study as undertreatment of
depression has already been the focus of many studies in the
past.[11–16] Moreover, the NESDA study is not suitable for
answering this question. It is a naturalistic study and part of the
study population did not seek any help. It is therefore impossible to
determine which patients are ‘‘undertreated’’ by their GP and
which did not seek help for their psychological complaints.
Implications for future research and clinical practice
In conclusion, the current study provides a unique insight into
the justification of the prescription of antidepressants in Dutch
primary care. In contrast to the scarce literature, the rate of
overtreatment with antidepressants in the present study was low.
Another interesting finding is that overtreatment is not so much
due to treatment of mild forms of depression or patients without
psychiatric diagnoses, but rather to an excessive duration of
antidepressant treatment in patients with remitted (recurrent)
MDD. This latter finding presents several implications for clinical
practice. First, projects on optimizing treatment with antidepres-
sants in primary care, should not focus on reducing overtreatment
but on identifying patients who do not need antidepressants
anymore. Second, GPs should be aware that apparently many
patients tend to continue the antidepressant over many years.
Which of these patients might be able to stop the antidepressant is
unclear. Therefore, further studies addressing this question are
warranted before starting campaigns to reduce the use of
antidepressants in primary care.
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